STEROHCA: Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest

Sponsor

Christian Hassager (Other)

Overall Status

Recruiting

CT.gov ID

NCT04624776

Collaborator

(none)

120

Enrollment

Locations

Arms

25.7

Anticipated Duration (Months)

Patients Per Site

2.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Comatose patients resuscitated from Out-of-Hospital Cardiac Arrest (OHCA) often develop a complicated systemic inflammatory response and have a poor prognosis with neurological damage being the most common cause of death. This study will investigate the anti-inflammatory and neuroprotective effect of early treatment with the glucocorticoid methylprednisolone measured by interleukin-6 and neuron-specific enolase levels in resuscitated comatose OHCA-patients.

Condition or Disease	Intervention/Treatment	Phase
Out-Of-Hospital Cardiac Arrest Cardiac Arrest Cardiac Arrest With Successful Resuscitation Post Cardiac Arrest Syndrome Systemic Inflammatory Response Syndrome Neurological Injury	Drug: Methylprednisolone Drug: Isotonic saline	Phase 2

Detailed Description

BACKGROUND:

Each year approximately 5400 individuals suffer from Out-of-Hospital Cardiac Arrest (OHCA) in Denmark and despite an improved prognosis 30-day mortality is around 90%. For OHCA patients resuscitated successfully and admitted to an Intensive Care Unit (ICU) the 30-day mortality remains higher than 50% due to a complicated systemic response, referred to as the Post Cardiac Arrest Syndrome (PCAS). PCAS consists of four interacting components: 1) ischemic/reperfusion brain injury, 2) myocardial dysfunction, 3) a systemic inflammatory response and 4) persistent stress from the triggering cause of the cardiac arrest, e.g. acute myocardial infarction. PCAS progresses during the first 1-2 days following resuscitated cardiac arrest, and the treatment aims to reduce neurologic injury by cooling the patient to 33-36° C, circulatory support with vasopressors, inotropics or mechanical devices as well as identification and treatment of reversible causes to the cardiac arrest, e.g. acute revascularization of an AMI.

Several studies have shown that the systemic inflammatory response is associated with a high risk of poor outcome following OHCA. Inflammatory markers associated with poor outcome include interleukin (IL) 6, high sensitivity C-reactive protein (hsCRP), leucocytes, IL-1b, IL-10, IL-13, tumor necrosis factor alpha (TNF-alpha) and procalcitonin. Despite of this, there is no specific treatment that addresses this complicated and life-threatening systemic response, and guidelines remain inconclusive in this field.

Anoxic irreversible brain injury remains the leading cause of death following resuscitated OHCA. The complex mechanism is one of the components in the PCAS and is thought to develop due to neuron apoptosis and reperfusion/ischemic injury. Further, the biomarker neuron-specific enolase (NSE) is correlated to neuron damage in the blood stream and has a strong predictive value for poor outcome following OHCA. Inhibiting the causes of the systemic inflammatory response and thereby potentially the brain injury in the very early stages following resuscitation from OHCA may therefore be key to optimizing post-cardiac arrest care.

Following resuscitated OHCA, the function of the adrenal gland is compromised due to global ischemia and reduced levels of the hormone steroid, glucocorticoid, are produced. Glucocorticoid has an important role in several physiologic processes including an anti-inflammatory systemic response. As a result, resuscitated cardiac arrest patients are affected by a severe inflammatory response, while the natural defense mechanism of the body to modulate inflammation is suppressed. Systemic treatment with steroids serves as an anti-inflammatory mediator and counteracts acute microcirculation injury and free radical formation, resulting in diminished vasodilation and reduction of edema, e.g. brain edema. Two small studies have shown signs of improved survival and neurologic outcome among patients who was given injections with glucocorticoids after in-hospital cardiac arrest. The incidence of adverse events was not higher in patients receiving glucocorticoids. Long-term treatment with glucocorticoids is associated with a series of side effects, whereas short-term treatment only has a few side effects. Systemic treatment with glucocorticoids could therefore be an important and safe factor in the treatment of resuscitated cardiac arrest patients that could potentially improve survival and neurological outcome.

Methylprednisolone and other glucocorticoids are used in pulse doses (>250 mg prednisolone equivalent a day) in various acute immunologically mediated conditions/diseases such as organ transplantation to prevent organ rejection and certain rheumatic diseases with acute deterioration. All these conditions are associated with a severe inflammatory response, as seen in PCAS, and therefore methylprednisolone doses as high as 30 mg/kg (equivalent of 2.1 g for a person weighing 70 kg) are used in pulse therapy to obtain an adequate response and effect. Further, the advantage of pulse dose glucocorticoid treatment is better efficacy, but also a decrease in side effects due to a reduced need for longer lasting therapy exceeding days or weeks. The literature reports of possible cardiovascular side effects as bradycardia and arrhythmias associated to infusion of pulse doses of methylprednisolone/glucocorticoids if given within a short period of time, but the evidence is limited and not well supported. The Danish summary of product characteristics recommends an initial infusion of Solu-Medrol to be administered over a period of at least five minutes.

Based on the above knowledge the intervention in this study is 250 mg of methylprednisolone administered intravenously as a bolus infusion over five minutes.

In summary, following resuscitated OHCA, PCAS, a severe and life-threatening condition, is often developed. PCAS is associated with increased mortality and poor neurological outcome. Inhibition of this inflammatory response may have an important, yet relatively unknown, role in post-cardiac arrest care.

HYPOTHESIS:

Bolus infusion of 250 mg methylprednisolone in the pre-hospital setting will inhibit the systemic inflammatory response and minimize the degree of neurological injury in comatose, resuscitated Out-of-Hospital Cardiac Arrest (OHCA) patients.

SAMPLE SIZE:

The trial is powered at the co-primary endpoint. The investigators chose a priori to power the trial at the 'weakest' of the two endpoints, ensuring a sufficient power for both endpoints. As the investigators were not able to find data regarding the effect of methylprednisolone on IL-6 levels or NSE levels from OHCA admission, the trial was powered towards a single measurement drawn 48 hours after admission. In 171 patients from the investigators institution the mean (logarithmically transformed to approximate normal distribution) IL-6 level after 48 hours from admission was 4.19±1.27 (unpublished data). The investigators assumed that methylprednisolone would reduce the IL-6 level by 20%. With an α-level of 0.025, the trial would achieve a power of 0.90 if 112 patients were included. The mean (logarithmically transformed to approximate normal distribution) NSE level after 48 hours was 3.21±0.96 after 48 hours from admission (unpublished data). The investigators assumed that methylprednisolone would reduce the NSE level by 20%. With an α-level of 0.025, the trial would achieve a power of 0.90 if 114 patients were included. The investigators aimed to include 120 patients, to adjust for missingness due to withdrawn consent. Further, since a proportion of the patients were expected to die before complete assessment of the co-primary endpoint (i.e. blood sampling at 72 hours), randomization of patients will continue until a total of 120 patients have survived to blood sampling at 72 hours.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

120 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Investigator-initiated, 1:1 randomized, multicenter, double-blind, placebo-controlled clinical trial. A minimum of 120 unconscious OHCA patients will be randomized 1:1 after 5 minutes of sustained ROSC to an infusion of 250 mg (4 mL) methylprednisolone in the pre-hospital setting. The methylprednisolone will be given as a bolus infusion of 1 x 250 mg (1 x 4 mL) over a period of 5 minutes. Patients allocated to placebo will receive 4 mL of isotonic saline (NaCl 0.9%).Investigator-initiated, 1:1 randomized, multicenter, double-blind, placebo-controlled clinical trial. A minimum of 120 unconscious OHCA patients will be randomized 1:1 after 5 minutes of sustained ROSC to an infusion of 250 mg (4 mL) methylprednisolone in the pre-hospital setting. The methylprednisolone will be given as a bolus infusion of 1 x 250 mg (1 x 4 mL) over a period of 5 minutes. Patients allocated to placebo will receive 4 mL of isotonic saline (NaCl 0.9%).

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Steroid Treatment as Anti-inflammatory and Neuroprotective Agent Following Out-of-Hospital Cardiac Arrest. A Randomized Trial

Actual Study Start Date :

Oct 10, 2020

Anticipated Primary Completion Date :

May 1, 2022

Anticipated Study Completion Date :

Dec 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Methylprednisolone A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.	Drug: Methylprednisolone A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion. Other Names: Solu-Medrol
Placebo Comparator: Isotonic saline A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).	Drug: Isotonic saline A bolus infusion of 4 mL isotonic saline (NaCl 0.9%). Other Names: Placebo

Arm

Intervention/Treatment

Active Comparator: Methylprednisolone

A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.

Drug: Methylprednisolone

A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.

Other Names:

Solu-Medrol

Placebo Comparator: Isotonic saline

A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).

Drug: Isotonic saline

A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).

Other Names:

Placebo

Outcome Measures

Primary Outcome Measures

Concentration of IL-6 [Daily measurements from admission to 72 hours after admission]
Interleukin 6 (ng/L)
Concentration of NSE [Daily measurements from admission to 72 hours after admission]
Neuron-specific-enolase (ng/L)

Secondary Outcome Measures

Markers of inflammation, biomarkers [Daily measurements the first three days following admission]
High sensitivity C-reactive protein (hsCRP, mg/L) and plasma cytokine levels exemplified by IL-6 (ng/L)
Markers of inflammation, cell count [Daily measurements the first three days following admission]
Leucocyte- and differential count (thousand cells/µL)
Markers of kidney and hepatic injury [Daily measurements the first three days following admission]
Creatinine, ALAT, ASAT, BF and bilirubin (all in mg/L)
Marker of the coagulation system, biomarker [Plasma fibrinogen the first three days from admission]
Plasma fibrinogen (mg/L)
Marker of the coagulation system, functional analysis [Thromboelastography at admission and at 48 hours]
Thromboelastography (TEG, measured in minutes)
Hemodynamics, Swan-Ganz catheter [Daily Swan-Ganz catheter measurements the first five days from admission]
Measurements on Swan-Ganz catheter (CVP, PAP, PCWP - all in mmHg)
Hemodynamics, arterial blood gasses (Lactate) [Arterial blood gasses bihourly the first 36 hours]
Arterial blood gasses (Lactate in mmol/L)
Hemodynamics, arterial blood gasses [Arterial blood gasses bihourly the first 36 hours]
Arterial blood gasses (PaO2 and PaCO2 in kPa)
Neuroprotection, biomarkers [Biomarkers the first three days from admission]
Biomarkers TAU, NFL, NFM, NFH and GFAP (all in mmol/L)
Cardiac protection, biomarkers [Biomarkers the first three days from admission]
TnT, TnI and CKMB (all in mmol/L).
Clinical endpoint, survival [180 days following discharge]
Survival (yes/no, register based data from "The Medical Register of Births and Deaths" in Denmark)
Clinical endpoint, neurological outcome by mRS score [After five days of admission and at 30- and 180- days following discharge]
Neurological outcome (modified Rankin Scale score, 0-6 symptom scale with higher scores indicating more severe symptoms)
Safety, adverse events [From admission till 7 days following admission]
Cumulated incidence of adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age ≥18 years
OHCA of presumed cardiac cause
Unconsciousness (GCS ≤8) upon pre-hospital randomization
Sustained ROSC for at least 5 minutes
Randomization and start of study medicine infusion within 30 minutes of sustained ROSC.